CRISPR Therapeutics announces proposed public offering of common shares
CRISPR Therapeutics announced it is commencing an underwritten public offering of $200,000,000 of its common shares. In addition, the underwriters will have a 30-day option to purchase up to $30,000,000 of additional common shares at the public offering price less the underwriting discount. September 19, 2018